It was a day of good news, not-so-good news, and good-news-elsewhere for AstraZeneca Plc (AZN). The pharmaceutical giant released a batch of clinical trial results, and the story depends entirely on which patient population you're looking at.
First up: topline data from the Phase 3 program for a drug called efzimfotase alfa (try saying that three times fast). It's being tested for hypophosphatasia, or HPP, which is a rare, inherited metabolic disorder. In simple terms, mutations in a specific gene lead to soft, poorly mineralized bones—a condition similar to rickets.
The big idea here was to see if this new enzyme replacement therapy could work for a broad group of HPP patients, from kids to adults, and do so with fewer injections than the existing treatment, Strensiq.
The Kids Are Alright
Let's start with the good part. In children, the drug looks like a winner. In a trial called MULBERRY, which enrolled kids aged 2 to under 12 who hadn't been on the older drug, efzimfotase alfa hit its primary endpoint. The company says it showed "statistically significant and clinically meaningful improvements in bone health."
Another trial, CHESTNUT, looked at patients switching from Strensiq to the new drug. That study found the therapy was well-tolerated and maintained those bone health improvements for at least 25 weeks. So far, so good for the pediatric side of the business.
The Adulting Part Was Harder
Now, for the trickier bit. When they tested the drug in adolescents and adults in a trial named HICKORY, things didn't go as planned. The primary goal was to see improvement in a standard test of endurance called the Six-Minute Walk Test. The drug didn't achieve statistical significance on that measure.
Why? According to the company, it was largely "attributed to stronger-than-expected placebo responses in adult-onset patients." In other words, the group of patients who thought they might be getting the drug but were actually getting a sugar pill did surprisingly well, making it harder for the real drug to show a clear win.
It's not all bad news for the grown-ups, though. The therapy did show what the company calls "nominal improvements" in fatigue. More importantly, it demonstrated "clinically meaningful benefits in mobility, pain reduction, and physical function" in key subgroups, particularly those whose disease started in childhood. Long-term data also suggested patients kept improving through 48 weeks, and even those who started on placebo saw gains once they switched to the real treatment.
Meanwhile, Over in the Lungs...
Perhaps to balance the scales, AstraZeneca also dropped positive news about a completely different drug on Friday. Topline results from two Phase 3 trials—OBERON and TITANIA—for a drug called tozorakimab in chronic obstructive pulmonary disease (COPD) were a success.
The trials met their primary endpoint in the main population of former smokers. They also succeeded in the overall population, which included both former and current smokers, and patients across all ranges of a specific blood cell count and all stages of lung function severity. In the race to treat smoker's lung, this is a solid step forward.
The market seemed to focus on the positives. AstraZeneca shares were up 1.20% at $196.21 on the day of the announcement. It's a classic pharma story: one trial misses, but promising data elsewhere and in key patient subgroups keeps hope—and the stock price—alive.
